Mesoridazine

Cat. No.:	HY-B1482A
CAS No.:	5588-33-0
Molecular Formula:	$C_{21}H_{26}N_2OS_2$
Molecular Weight:	386.57
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Mesoridazine (TPS-23) , a metabolite of Thioridazine (HY-B0965A), acts as an orally active phenothiazine antipsychotic agent . Mesoridazine is a potent and rapid open-channel blocker of human ether-a-go-go related gene (hERG) channels and blocks hERG currents with an IC_{50} of 550 nM (at 0 mV) in human embryonic kidney 293 cells[1].Mesoridazine can be used for the research of schizophrenia, as well as certain other psychiatric disorders[1][2].
IC_{50} & Target	IC_{50}: hERG currents[1]
In Vitro	Mesoridazine blocks human ether-a-go-go-related gene (HERG) currents in a concentration-dependent manner (IC_{50} = 550 nM at 0 mV), block increased significantly over the voltage range where HERG activates and saturates at voltages eliciting maximal HERG channel activation[1]. Mesoridazine (15 mM; 24 h) shows total absorption of 15.94 ± 4.04% and 39.24 ± 5.11% in nude mouse and pig skin, respectively[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Mesoridazine (15 mM; topical administration; once or daily for 7 consecutive days) displays potent activity and a long period of analgesia at blocking cutaneous pain[3]. Mesoridazine (15 mM) shows intradermal concentration of 0.34 0.74 nmol/mg after topical application on nude mouse back for 6 h[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old female nude mice[3]
Dosage:	15 mM
Administration:	Topical administration, once (analgesia test) or daily for 7 consecutive days (irritation test)
Result:	Showed analgesic effect. A slight transepidermal water loss (TEWL) increased from 7.8 to 9.9 g/m^2/h was observed.

REFERENCES

[1]. Liu KS, et al. Topically applied mesoridazine exhibits the strongest cutaneous analgesia and minimized skin disruption among tricyclic antidepressants: The skin

absorption assessment. Eur J Pharm Biopharm. 2016 Aug;105:59-68.

[2]. Zhi Su, et al. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. J Mol Cell Cardiol. 2004 Jan;36(1):151-60.

[3]. I S M Salih, et al. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther. 2007 Nov;82(5):548-54.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA